# A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects

> **NCT02088918** · PHASE1 · COMPLETED · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 40 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Nateglinide
- **DRUG:** Nateglinide/Metformin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02088918
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2012-12
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02088918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02088918, "A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02088918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*